FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043567553> ?p ?o ?g. }

• W2043567553 endingPage "283" @default.
• W2043567553 startingPage "278" @default.
• W2043567553 abstract "Abstract Progressive restrictive defect with increasing age, obstructive lung disease, and bronchodilator responsiveness have been reported in sickle cell disease (SCD). Because airway hyperreactivity (AHR) can be underestimated when assessed by bronchodilator responsiveness in patients with normal baseline lung function, the aim of this study was to investigate the prevalence of AHR in SCD by cold-air bronchial provocation testing, and to assess whether AHR can be present in symptom-free patients with SCD. Forty patients aged 6 to 19 years (mean, 10.7 years ± 3.5 SD) performed pulmonary function tests. Eighteen were known to have a history of reactive airway disease (RAD group), and 22 had no known history of RAD (non-RAD group). A control group, aged 6 to 17 years (mean, 10.5 ± 3.1 years), consisted of 10 siblings of the non-RAD SCD group. There were no significant differences in age and height among the groups. If the forced expiratory volume in 1 second (FEV1 ) was greater than 70%, cold air challenge (CACh) was performed; if the FEV1 was less than 70%, aerosolized bronchodilator therapy was given. A decrease in FEV1 of more than 10% after CACh or an increase in FEV1 of 12% or greater after bronchodilator inhalation was considered evidence of AHR. In the RAD group, the total lung capacity was 88.9% ± 14.0% of race-corrected predicted values, the forced vital capacity was 91.2% ± 12.6%, and FEV1 was 85.3% ± 16.2%. The mean maximal percent fall in FEV1 after CACh ( n = 13) was 18.5% ± 9.6% and was greater than 10% in 11 of 13 patients. The mean increase in FEV1 after bronchodilator therapy ( n = 5) was 11.5% ± 8.3%, and it was greater than 12% in 4 of 5 patients. In the non-RAD group the baseline total lung capacity was 101.6% ± 11.7%, forced vital capacity was 95.5% ± 10.2%, and FEV1 was 93.3% ± 13.2%. The mean maximal percent fall in FEV1 after CACh ( n = 19) was 14.1% ± 8.8% and was greater than 10% in 13 of 19 patients. The mean increase in FEV1 after bronchodilator therapy ( n = 3) was 14.7% ± 11.3%, and was 12% or greater in 1 of 3 patients. In the control group the baseline total lung capacity was 105.7% ± 12.1%, forced vital capacity was 96.2% ± 11.1%, and FEV1 was 92.9% ± 10.3%. The mean maximal percent fall in FEV1 was 5.0% ± 2.5%, and was greater than 10% in none of 10 patients. The prevalence of AHR in the control group, the RAD group, and the non-RAD group was zero, 83%, and 64%, respectively ( p" @default.
• W2043567553 created "2016-06-24" @default.
• W2043567553 creator A5002750297 @default.
• W2043567553 creator A5016632165 @default.
• W2043567553 creator A5022310299 @default.
• W2043567553 creator A5049623621 @default.
• W2043567553 date "1997-08-01" @default.
• W2043567553 modified "2023-09-26" @default.
• W2043567553 title "Airway hyperreactivity in children with sickle cell disease" @default.
• W2043567553 cites W1972658294 @default.
• W2043567553 cites W1974156899 @default.
• W2043567553 cites W1992059050 @default.
• W2043567553 cites W1993716882 @default.
• W2043567553 cites W1996176705 @default.
• W2043567553 cites W1998239701 @default.
• W2043567553 cites W2011178759 @default.
• W2043567553 cites W2019907816 @default.
• W2043567553 cites W2022726688 @default.
• W2043567553 cites W2024063751 @default.
• W2043567553 cites W2029426040 @default.
• W2043567553 cites W2041624203 @default.
• W2043567553 cites W2047205245 @default.
• W2043567553 cites W2051489487 @default.
• W2043567553 cites W2066577492 @default.
• W2043567553 cites W2083549350 @default.
• W2043567553 cites W2099191183 @default.
• W2043567553 cites W2111868282 @default.
• W2043567553 cites W2147249745 @default.
• W2043567553 cites W2148005482 @default.
• W2043567553 cites W2182618397 @default.
• W2043567553 cites W3113247834 @default.
• W2043567553 cites W4249200669 @default.
• W2043567553 doi "https://doi.org/10.1016/s0022-3476(97)70166-5" @default.
• W2043567553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9290616" @default.
• W2043567553 hasPublicationYear "1997" @default.
• W2043567553 type Work @default.
• W2043567553 sameAs 2043567553 @default.
• W2043567553 citedByCount "130" @default.
• W2043567553 countsByYear W20435675532012 @default.
• W2043567553 countsByYear W20435675532013 @default.
• W2043567553 countsByYear W20435675532014 @default.
• W2043567553 countsByYear W20435675532015 @default.
• W2043567553 countsByYear W20435675532016 @default.
• W2043567553 countsByYear W20435675532017 @default.
• W2043567553 countsByYear W20435675532018 @default.
• W2043567553 countsByYear W20435675532019 @default.
• W2043567553 countsByYear W20435675532020 @default.
• W2043567553 countsByYear W20435675532021 @default.
• W2043567553 countsByYear W20435675532022 @default.
• W2043567553 countsByYear W20435675532023 @default.
• W2043567553 crossrefType "journal-article" @default.
• W2043567553 hasAuthorship W2043567553A5002750297 @default.
• W2043567553 hasAuthorship W2043567553A5016632165 @default.
• W2043567553 hasAuthorship W2043567553A5022310299 @default.
• W2043567553 hasAuthorship W2043567553A5049623621 @default.
• W2043567553 hasConcept C105922876 @default.
• W2043567553 hasConcept C126322002 @default.
• W2043567553 hasConcept C141071460 @default.
• W2043567553 hasConcept C177713679 @default.
• W2043567553 hasConcept C187212893 @default.
• W2043567553 hasConcept C203014093 @default.
• W2043567553 hasConcept C2779134260 @default.
• W2043567553 hasConcept C71924100 @default.
• W2043567553 hasConceptScore W2043567553C105922876 @default.
• W2043567553 hasConceptScore W2043567553C126322002 @default.
• W2043567553 hasConceptScore W2043567553C141071460 @default.
• W2043567553 hasConceptScore W2043567553C177713679 @default.
• W2043567553 hasConceptScore W2043567553C187212893 @default.
• W2043567553 hasConceptScore W2043567553C203014093 @default.
• W2043567553 hasConceptScore W2043567553C2779134260 @default.
• W2043567553 hasConceptScore W2043567553C71924100 @default.
• W2043567553 hasIssue "2" @default.
• W2043567553 hasLocation W20435675531 @default.
• W2043567553 hasOpenAccess W2043567553 @default.
• W2043567553 hasPrimaryLocation W20435675531 @default.
• W2043567553 hasRelatedWork W2024965181 @default.
• W2043567553 hasRelatedWork W2082482010 @default.
• W2043567553 hasRelatedWork W2350476764 @default.
• W2043567553 hasRelatedWork W2402299764 @default.
• W2043567553 hasRelatedWork W2893076153 @default.
• W2043567553 hasRelatedWork W2992709694 @default.
• W2043567553 hasRelatedWork W4230410841 @default.
• W2043567553 hasRelatedWork W4238599390 @default.
• W2043567553 hasRelatedWork W4252371801 @default.
• W2043567553 hasRelatedWork W4295775062 @default.
• W2043567553 hasVolume "131" @default.
• W2043567553 isParatext "false" @default.
• W2043567553 isRetracted "false" @default.
• W2043567553 magId "2043567553" @default.
• W2043567553 workType "article" @default.